Vanguard Global Advisers’s Inhibrx INBX Stock Holding History

Vanguard Global Advisers’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$701K	Hold	7,402	–	–	﹤0.01%	1948
2026 Q1	$498K	Buy	+7,402	New	+$549K	﹤0.01%	2054

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's INBX Position: Q2 2026 in Review

Vanguard Global Advisers held its Inhibrx (INBX) position steady in Q2 2026 at 7,402 shares worth $701K. The position accounts for ﹤0.01% of the portfolio, ranked #1948.

Vanguard Global Advisers first reported a position in INBX in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Vanguard Global Advisers held 7,402 shares of Inhibrx worth $701K as of Q2 2026.
Vanguard Global Advisers left its Inhibrx share count unchanged in Q2 2026.
Inhibrx made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1948 holding.
Vanguard Global Advisers first reported a position in Inhibrx in Q1 2026 and has held it in 2 quarters since.
161 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.